Gustav Gaudernack

Dr. Gustav Gaudernack
Dept. of Immunology
Institute for Cancer Research
Oslo University Hospital, 
The Norwegian Radium Hospital
Tel +47 22 78 13 26




The major aim of the immunotherapy group within the framework of SFI-CAST is to

develop novel forms of immunotherapy for cancer targeting cancer stem cell, and to test these in early phase clinical trials.



Alsoe L, Stacy J E, Fosså A, Funderud S, Brekke O H and Gaudernack G. Identification of prostate cancer antigens by automated high-throughput filter immunoscreening.J. Immunol. Methods 330:12-23 (2008).


Copier J, Dalgleish AG, Britten C M, Finke L H, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Hakansson L. Improving the efficacy of immunotherapy. Eur J Cancer. 2009 May;45(8):1424-31. Epub 2009 Jan 21. Review.


Kyte J A, Trachsel S, Risberg B, Thor Straten P, Lislerud K and Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long term survivors after cancer vaccination. Cancer Immunol Immunother. 2009 Oct;58(10):1609-26. Epub 2009 Feb 17.


Kloster MM, Hafte TT, Moltzau LR, Naderi EH, Dahle MK, Skålhegg BS, Gaudernack G, Levy FO, Naderi S, Blomhoff HK. EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase. Cell Signal. 2008 Jun;20(6):1169-78. Epub 2008 Apr 10.


Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol. 2009 Jul-Aug;33(4):175-81.


Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, Aarvak T. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods. 2010 Apr 15;355(1-2):52-60. Epub 2010 Feb 19.




Gustav Gaudernack laboratory